BridgeMD
New treatment option for Cytomegalovirus Infections
Official title ATG Individualized Dosing Model in URD-PBSCT.
ClinicalTrials.gov ID: NCT06572462
What this study is testing
What is individualized ATG dosing strategy?
individualized ATG dosing strategy is an investigational medicine, being studied as a potential treatment for cytomegalovirus infections.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure. However, overexposure to ATG may increase cytomegalovirus (CMV), Epstein-Barr virus (EBV) reactivation, non-relapse mortality, and disease recurrence.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 14 to 65
You may be able to join if
- Patients with malignant hematological tumors who have indications for allogeneic hematopoietic stem cell transplantation.
- HLA-matched unrelated donor
- Patient age ≥14 years old and ≤65 years old
- ALT and AST ≤ 2.5 times the upper limit of normal values, bilirubin ≤ 2 times the upper limit of normal values
- Creatinine ≤ high limit of normal value
You likely can't join if
- Unrelated donor who is not HLA matched
- No indication for allogeneic hematopoietic stem cell transplantation
- Patient age \ 65 years old
- The donor or recipient are pregnant
- Suffering from mental illness or other conditions and being unable to proceed as planned
See the full eligibility criteria
- Patients with malignant hematological tumors who have indications for allogeneic hematopoietic stem cell transplantation.
- HLA-matched unrelated donor
- Patient age ≥14 years old and ≤65 years old
- ALT and AST ≤ 2.5 times the upper limit of normal values, bilirubin ≤ 2 times the upper limit of normal values
- Creatinine ≤ high limit of normal value
- No uncontrollable infection or serious mental illness
- Physical strength score is 0-2 (ECOG)
- Sign the informed consent form
- Unrelated donor who is not HLA matched
- No indication for allogeneic hematopoietic stem cell transplantation
- Patient age \ 65 years old
- The donor or recipient are pregnant
- Suffering from mental illness or other conditions and being unable to proceed as planned
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 14 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.